Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;34(10):4358-4368.
doi: 10.1007/s00464-019-07206-x. Epub 2019 Oct 23.

Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients

Gennaro Nappo  1 , Damiano Gentile  2 , Jacopo Galvanin  2 , Giovanni Capretti  2 , Cristina Ridolfi  2 , Tommasangelo Petitti  3 , Paola Spaggiari  4 , Silvia Carrara  5 , Francesca Gavazzi  2 , Alessandro Repici  5   6 , Alessandro Zerbi  2   6
Affiliations

Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients

Gennaro Nappo et al. Surg Endosc. 2020 Oct.

Abstract

Background: Trans-duodenal ampullectomy (TDA) is a surgical option for the treatment of selected ampullary neoplasms. The aim of this study was to evaluate our experience with TDA for the treatment of ampullary neoplasms, focusing on indications, technical aspects, and short- and long-term outcomes.

Methods: All TDAs for ampullary neoplasms performed between January 2010 and December 2018 at our institution were retrospectively evaluated. Patients had ampullary neoplasms with low-grade dysplasia or in situ carcinoma (Tis) not suitable for an endoscopic approach, ampullary carcinoma unfit for pancreaticoduodenectomy (PD), or ampullary neuroendocrine G1-tumours.

Results: Thirty-six patients were included in the study: 9 (25.0%) with neoplasms with low-grade dysplasia, 4 (11.1%) with G1 neuroendocrine tumours and 23 (63.9%) with Tis or invasive carcinoma. Mean operative time was 252.5 min. Overall and severe (Clavien-Dindo > IIIa) morbidity rate was 44.4% and 13.9%, respectively. No 90-day mortality was observed. At follow-up, no deaths were observed and local recurrence rate was 11.1% for patients with ampullary adenomas with low-grade dysplasia. Among four patients with neuroendocrine neoplasms, only one developed recurrence (pulmonary). Tis, T1 and T2 lesions were found in 16 (69.6%), 2 (8.7%) and 5 (21.7%) patients, respectively: recurrence occurred in 3 patients with Tis lesions (one malignant), no patients with T1 neoplasms and 2 patients with T2 lesions (3 patients had a survival of > 3 years).

Conclusions: TDA is a feasible and effective surgical procedure for the treatment of ampullary adenomas with low-grade dysplasia when endoscopic approach is contraindicated or has failed. For lesions with evidence of malignancy, TDA seems to be an oncological safe procedure for Tis ampullary cancer and a good palliative procedure for patients unfit for PD. Moreover, TDA may be appropriate for the treatment of G1 ampullary neuroendocrine neoplasms. A large multicentre study of TDA for early ampullary cancers is needed.

Keywords: Ampullary adenomas; Ampullectomy; Early ampullary cancer; Endoscopic ampullectomy; Surgical ampullectomy; Trans-duodenal ampullectomy.

PubMed Disclaimer

References

    1. Surveillance, Epidemiology and End Results (SEER). SEER stat database: incidence-SEER regs limited use. http://www.seer.cancer.gov . Accessed 2019
    1. Treitschke F, Beger HG (1999) Local resection of benign periampullary tumors. Ann Oncol 10(Suppl 4):212–214 - DOI
    1. Stolte M, Psherer C (1996) Adenoma-carcinoma sequence in the papilla of Vater. Scand J Gastroenterol 60:497–500
    1. Hernandez LV, Catalano MF (2008) Endoscopic papillectomy. Curr Opin Gastroenterol 24:617–622 - DOI
    1. De Palma GD (2014) Endoscopic papillectomy: indications, techniques, and results. World J Gastroenterol 20:1537–1543 - DOI

LinkOut - more resources